BUSINESS DEVELOPMENT SPECIALIST

TRIUMF Innovations is the commercialization arm of TRIUMF, Canada’s particle accelerator centre. We are dedicated to linking cutting-edge science and technology to tangible business opportunities. TRIUMF Innovations acts as a connector to the business world by providing market opportunities for applied physics-based technologies, that emerge from the TRIUMF network – by streamlining access to TRIUMF’s world-class expertise and infrastructure, and by connecting TRIUMF researchers and technologies to the world. The position is to accelerate the development of new commercialization opportunities by working closely with TRIUMF researchers to advance their projects, seek out new partners and secure funding.

RESPONSIBILITIES • Interacting with TRIUMF researchers to identify new technologies and to assess their commercial potential. • Identifying and contacting new business opportunities and industry partners for TRIUMF researchers and technologies. • Developing working prototypes and proof-of-concept studies for emerging technologies. • Developing partnering/funding strategies advance commercialization of technologies. • Preparing business cases or plans. • Facilitating the creation of technology prototypes or demonstration projects. • Preparing funding proposals to various government programs that support commercialization of new technology. • Researching market opportunities, including industry trends and dynamics. • Building relationships, collaborations and partnerships with researchers and industry partners.

KNOWLEDGE AND SKILLS: The incumbent must have basic experience about TRIUMF technologies and services:
• Experience in developing presentations, proposals, pitches, grant applications for academic researchers, government funders, as well as industrial partners and private sector investors. • Excellent communications and interpersonal skills. • Good understanding of the types of research and development at TRIUMF. • Demonstrated ability to drive multiple projects to completion by deadline. • Work to plan, advance and complete complex projects to achieve milestones and deadlines. • Use independent judgment to drive projects with limited supervision. • Manage confidential information.

MINIMUM QUALIFICATIONS AND YEARS OF EXPERIENCE: • A Master’s or PhD in physics or engineering. • Strong communications and outreach skills. • Some business education or experience preferred. • Ability to work independently.
Length of position: intended to be a 1-year term plus a one-year extension.

Total Rewards At TRIUMF Innovations, we value our employees and are committed to providing a competitive total rewards package. We offer comprehensive benefits that promote the well-being and security of our staff and provide an excellent opportunity to grow your career in a high-profile national research facility, where you can make a difference.

Salary Information: $55,000 - $70,000 per year plus benefits

Benefits Information: • TRIUMF Innovations paid dental, extended health, vision care, emergency travel assistance, EAP, Life Insurance, and supplementary Wellness Benefits. • Excellent Employee Pension Plan. • Disability benefits, and optional additional Life insurance and AD&D. • Generous time away. • Maternity and paternity leaves and top-ups.

Application closing date: August 15, 2024. Submit Applications to: info@triumfinnovations.ca

As a requirement of this position, the successful candidate will need to provide acceptable proof that they have been fully vaccinated for COVID-19 or demonstrate that they are unable to be vaccinated against COVID-19 for reasons protected under the BC Human Rights Code. TRIUMF will grant reasonable accommodation requests up to the point of undue hardship. Apply now and be part of our extraordinary journey. Learn more about the work we do at TRIUMF Innovations. https://www.triumfinnovations.ca/ http://www.rarestdrug.com Equity, diversity, and inclusion are integral to excellence and enhance our ability to create knowledge and opportunity for all. Together, we are committed to building an inclusive culture that encourages, supports, and celebrates the voices of our employees, students, partners, and the people and communities we serve. As an equal opportunity employer, committed to diversity, we encourage applications from members of groups that have been marginalised on any grounds enumerated under the B.C. Human Rights Code. All qualified applicants will receive consideration for employment.

Contact information: Email: info@triumfinnovations.ca 4004 Wesbrook Mall - Vancouver, BC - V6T 2A3. TRIUMF Innovations is located on the traditional, ancestral, and unceded territory of the xwməθkwəy̓əm (Musqueam) People, who for millennia have passed on their culture, history, and traditions from one generation to the next on this site.

Training Opportunity: TRIUMF Innovations Commercialization Interns

April 19, 2024

Training Opportunity: TRIUMF Innovations Commercialization Interns

TRIUMF Innovations is the commercialization arm for TRIUMF, building commercialization programs using novel business models, partnerships and technology licenses. We are recruiting our new cohort of Commercialization Interns to provide students and researchers at TRIUMF with opportunities to gain valuable experience and practical skills in commercialization and entrepreneurship.

This program is open to current TRIUMF personnel who have approval from their direct supervisor and Associate Lab Director to spend 10%-20% of their time on commercialization projects over a 9-12-month period.

The Commercialization Intern will receive training and practical experience from the TRIUMF Innovations Team in: • technology assessments for novel discoveries and inventions at TRIUMF • building business/market cases for novel technologies • confidentiality agreements and intellectual property management • developing strategies for industry engagements.

Qualifications/Requirements • Must be a TRIUMF employee, graduate student or post-doctoral fellow for the entire internship • Must have pre-approval from their TRIUMF Direct Supervisor and Associate Lab Director

Desired Characteristics

• Proficiency in Microsoft Office Suite (Excel, Word, Powerpoint) • Interest and experience in business development and commercialization related to TRIUMF technologies • Demonstrated organizational skills, attention to detail, and accuracy • Excellent verbal and written communications skills • Self-started who can manage multiple tasks simultaneously with limited supervision • Ability to learn fast and achieve high level of results • Effective interpersonal skills • Ability to work in a team environment within a matrix organization

If you are interested, please email your cover letter and resume to Sangeeta Hussain: shussain@triumfinnovations.ca

Deadline to apply is May 17, 2024

If you have any questions, please do not hesitate to contact Sangeeta @ (604)222-7523.

Acquisition of ARTMS, TRIUMF Medical Isotope Spinoff, Demonstrates Value and Impact of Canada's Major Research Facilities

VANCOUVER, BC, April 11, 2024 /CNW/ - ARTMS Inc, originally a spin-off company from TRIUMF, Canada's particle accelerator centre, has been acquired by leading biopharma company Telix Pharmaceuticals in a US$82M deal that will expand the deployment of ARTMS' technology, supporting increased production of life-saving radiopharmaceuticals that can diagnose and treat cancer and other diseases.

"ARTMS is a tremendous example of how federal support for fundamental science can spur innovation and deliver real impact for Canadians and people around the world," said Nigel Smith, TRIUMF CEO and Executive Director. "Uniting 21 member universities and extensively connected to industry, TRIUMF is uniquely positioned to address the needs of Canada's R&D communities and advance the fundamental research that underpins our national innovation ecosystem."

As the largest-ever acquisition of a TRIUMF spin-off company, the deal stands as a striking symbol of the role of major science facilities in driving innovation and technological breakthroughs for the benefit of Canadians. ARTMS' success, which has been directly enabled by decades of federal and provincial investment in infrastructure and expertise at TRIUMF, also serves to retain Canada's status as a major player in the global life sciences innovation ecosystem.

"In response to a global isotope crisis triggered by the closing of the NRU reactor in Chalk River, ARTMS developed a unique technology that produces the world's most-used diagnostic imaging isotopes" Said Dr. Paul Schaffer, Director of TRIUMF Life Sciences and a founder of ARTMS. "We turned a major global challenge into an opportunity, and today what we do is fortifying isotope supply chains and empowering research on new, life-saving medical isotopes."

The company's 15-year journey from lab bench to market success has been made possible by a system of federal funding initiatives, including the NISP and ITAP programs, and funding from early-stage investor Quark Venture – Global Health Science Fund. The effort leveraged both a TRIUMF-led consortium of national partners including BC Cancer, the Centre for Probe Development and Commercialization, and Lawson Health Research Institute and TRIUMF's world-leading infrastructure and particle accelerator facilities in Vancouver.

"ARTMS is the result of the public and private sector working together to bring innovation to the world," said Kathryn Hayashi, CEO of TRIUMF Innovations, TRIUMF's commercialization arm. "Canada needs major infrastructure and national communities of experts and innovators like those that exist at TRIUMF to support and launch companies like ARTMS. ARTMS' story is a powerful example of what we can accomplish when we invest in fundamental science and work together."

Media contact:

TRIUMF

Stu Shepherd

Head, Communications

Sshepherd@triumf.ca

+1.604.222.7528

NSERC Awards Funding to TRIUMF and General Fusion to Develop State-of-the-Art Diagnostic System for LM26 Fusion Machine

3/27/2024 - TRIUMF, Canada’s particle accelerator centre, and General Fusion, an international leader in the development of commercial fusion energy, have received a Natural Sciences and Engineering Research Council of Canada (NSERC) Alliance grant to advance technology critical to measuring extreme temperatures inside a fusion machine. Grant funding of $800,000 over four years will support the design and delivery of an ultra-fast neutron spectrometer system to measure plasma temperatures at fusion conditions of over 100 million degrees Celsius (10 keV), a key technical milestone that General Fusion aims to achieve at large scale by 2025.

The neutron spectrometer system is a flagship project under the collaborative agreement signed by TRIUMF and General Fusion in 2023. Known for pushing the boundaries of science and innovation, TRIUMF will support General Fusion in developing a diagnostic system capable of precisely measuring neutron energies at a very high rate. Neutrons carry unique information about fusion reactions, and the system being built at TRIUMF and General Fusion will tag neutron interactions every nanosecond.

The highly advanced spectrometer will debut on General Fusion’s new Lawson Machine 26 (LM26) fusion demonstration machine to measure ion temperature, a critical plasma parameter, at peak compression of a magnetized plasma. Following LM26 operations, the company expects to upgrade the system for its planned near-commercial machine. To further support this trailblazing diagnostic work over the next four years, TRIUMF and General Fusion have enlisted experts from Simon Fraser University to design and implement a dedicated neutron test facility. Additionally, at the Université de Sherbrooke in Quebec, new Canadian single photon detection technology is being further developed and fabricated for the upgraded system that will be installed on General Fusion’s near-commercial machine.

“This exciting project highlights the deep technology collaboration happening across the country to advance Canadian fusion energy technology,” said Greg Twinney, CEO, General Fusion. “Together with top labs and universities, we are building and testing world-leading systems required to deliver commercial fusion energy to the grid by the early to mid-2030s.”

“This is a prime example of how TRIUMF expertise and infrastructure impact our world,” commented Kathryn Hayashi, CEO of TRIUMF Innovations, TRIUMF’s commercialization arm. “TRIUMF Innovations’ project with General Fusion uses our research and development work to fill a technology gap in high-rate neutron detection and provides potential for direct market outcomes in clean fusion energy, healthcare, and subatomic physics applications.”

About TRIUMF

Established in 1968 in Vancouver, TRIUMF is Canada’s particle accelerator centre. The lab is a hub for discovery and innovation inspired by a half-century of ingenuity in answering some of nature’s most challenging questions. From the hunt for the smallest particles in our universe and the origin of the elements that make up our world to research that advances the next generation of batteries, quantum computers or cures for cancer, TRIUMF is pushing frontiers in research, while training the next generation of leaders in science, medicine, and industry.

TRIUMF Media Relations

Stu Shepherd

Head, Communications

1.604.222.7528

sshepherd@triumf.ca

@TRIUMFLab

About General Fusion

General Fusion is pursuing a fast and practical approach to commercial fusion energy and is headquartered in Richmond, B.C., Canada. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com.

General Fusion Media Relations

media@generalfusion.com

+1-866-904-0995

CANADIAN MEDICAL ISOTOPE ECOSYSTEM ANNOUNCES DEVELOPMENT FUND TO FOSTER INNOVATION IN THE CANADIAN ISOTOPE INDUSTRY

11/16/2023 - The Canadian Medical Isotope Ecosystem Development Fund (CMIEDF) will invest in Canadian projects that advance medical isotope supply or develop emerging technologies in radiotherapeutics and diagnostics.

On November 16, the Canadian Medical Isotope Ecosystem (CMIE) – an initiative co-led by TRIUMF Innovations and the Centre for Probe Development and Commercialization (CPDC) – held an industry information session to announce the launch of the Canadian Medical Isotope Ecosystem Development Fund (CMIEDF).

The CMIE initiative’s goal is to accelerate R&D investment, collaboration, technology adoption, and training to enable Canada to lead in the innovation of medical isotopes. Through the new Development Fund, the CMIE will support industry collaboration and invest in promising Canadian projects that advance medical isotope supply or develop emerging technologies in radiotherapeutics and diagnostics.

“Our Government is committed to providing Canadians and medical workers with the best emerging medical technologies and opportunities. With the creation of the Canadian Medical Isotope Ecosystem, we continue to develop a strong domestic production of pharmaceutical products that will contribute to make Canada a prized destination for the medical isotope industry, while creating highly skilled jobs across Canada,” said Hon. François-Philippe Champagne, Minister of Innovation, Science, and Industry.

Funding for the CMIEDF will be drawn from the $35 million in launch funding awarded to the CMIE by Innovation, Science and Economic Development Canada’s Strategic Innovation Fund (SIF). Resources will be awarded directly to recipients and used to support them through the process of research, development, and commercialization. Funding for selected projects will increase as recipients achieve successful project milestones.

“This new project funding will provide resources to enable new collaborations to accelerate the development of the next generation of medical isotope innovations in Canada,” said Kathryn Hayashi, CEO of TRIUMF Innovations, Co-Lead for the CMIE.

“The CMIE Development Fund has been created with the goal of identifying, funding and ultimately commercializing promising early-stage medical isotope technologies and radiopharmaceutical research from across the country,” said Owen Roberts, CEO of the Centre for Probe Development and Commercialization, Co-Lead for the CMIE. “Our primary objective is to accelerate the development of great Canadian technology for the benefit of Canadian patients and the medical community.”

“It is exciting to see our government’s $35 million investment being used to advance Canada’s leadership in medical isotopes and radiopharmaceuticals,” said MP Pam Damoff, long-time champion and advocate for the Canadian isotope industry at the federal level. “This investment led to collaboration in the medical isotope sector with the creation of the Canadian Medical Isotope Ecosystem, and I have no doubt that the CMIEDF will lead to advances in medical isotopes to help Canada lead the world in medical isotopes.”

Opportunities for interested parties to receive funding support from the CMIEDF can be found on the Call for Proposals tab on our website. Applications for our first round of funding will open on December 15.

About CMIE

CMIE is an initiative created to accelerate R&D investment, collaboration, technology adoption and training to enable Canada to lead in the innovation of medical isotopes. Through a unique combination of co-investment, cross-industry collaboration, and IP development, we are building a strong national medical isotope innovation ecosystem.

For more information, please contact info@cmie.ca.

TRIUMF Innovations Newsletter

TRIUMF Innovations is Growing Canada’s Medical Isotope Ecosystem with $35M in New Strategic Innovation Funding

This past June, the Canadian government awarded $35 million to TRIUMF Innovations and the Centre for Probe Development and Commercialization (CPDC) to support the new Canadian Medical Isotope Ecosystem (CMIE) Fund. This funding will cover a five-year period and is aimed at initiatives that focus on the production, advancement and distribution of medical isotopes and radiopharmaceuticals in Canada. This investment isn’t just another sign of Canada’s trust in TRIUMF; it’s also further validation of the leading-edge work TRIUMF has been doing in the world of medical isotopes. Medical isotopes are vital to nuclear medicine, which uses radioactive tracers to diagnose and treat diseases. These isotopes are especially effective in tracking cancer and heart diseases. These isotopes are products of nuclear reactors and particle accelerators. Responding to the currently restricted global supply of in-demand medical isotopes, the CMIE will keep Canada at the forefront of nuclear medicine. The CMIE and its $35 million will help fund new medical isotope innovations that can improve the lives of Canadians receiving medical treatments, while also helping health care workers provide patients with better care. The CMIE ecosystem will also attract more than $75 million in investments, create or maintain over 600 highly skilled jobs for Canadians, and create 30 internship opportunities. Additionally, it is expected that the CMIE will launch three high-demand medical isotopes and related drug products into the marketplace and advance two medical isotopes from early stage to pre-clinical evaluation. “TRIUMF Innovations is proud to co-lead this important initiative with the CPDC,” said TRIUMF Innovations' President and CEO Kathryn Hayashi. “The new CMIE brings together government, industry, and academia to work collaboratively to build Canadian medical isotope capabilities and ensure Canada remains a leader in this high-growth sector.” CMIE projects include technology development initiatives from partners including Bruce Power, Canadian Nuclear Labs, McMaster University, as well as a new $5M Development Fund that will launch a Call for Proposals open to Canadian researchers and SMEs in 2023. The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, was equally excited about working with TRIUMF. “Our government is proud to partner with CPDC and TRIUMF Innovations as part of our Biomanufacturing and Life Sciences Strategy to create the Canadian Medical Isotope Ecosystem,” stated Champagne. “With this investment, we are making our country a major player in the global biomanufacturing and life sciences industry while creating good jobs for Canadians and stimulating the local economy." For more than 70 years now, Canada has played a key leadership role in the development and use of medical isotopes and has become a global leader in their production and supply. Since March 2020 alone, more than $2 billion has been invested in this emerging and critical field, resulting in 36 major new and expanded projects, all of which have elevated the capacities of Canada’s biomanufacturing and life sciences sectors. This is partly what led to the founding of TRIUMF Innovations in 2008. As the business interface and commercialization arm of TRIUMF, TRIUMF Innovations connects Canada's particle accelerator centre(TRIUMF) to the private sector via industry partnerships, licensing, and company creation. And, CMIE Co-Lead, the CPDC, has as its mission a very similar goal: to advance the “probes”—the chemical agents that carry medical isotopes to targets in the body—and hasten the discovery, development, and clinical research of other radiopharmaceuticals, and to provide a reliable supply of medicinal radiocompounds to Canada’s health care industry.

CMIE didn’t just emerge out of nowhere. Its creation, in many ways, came about because of work TRIUMF and TRIUMF Innovations has been focused on since 2018. It was in November of that year that Prime Minister Justin Trudeau announced the start of construction on the Institute for Advanced Medical Isotopes (IAMI). Enabled by the government of Canada, the province of British Columbia, and contributing research partners, including BC Cancer and the University of British Columbia, IAMI became operational in 2022 on the TRIUMF business campus. Dedicated to the research and production of medical isotopes, this state-of-the-art facility features an integrated series of labs and a TR-24 medical cyclotron, one of the most technologically advanced commercial cyclotrons in the world. It also produces a wide variety of medical isotopes critical for Canadian health research and clinical use. Further, IAIMI will continue to produce world-leading amounts of Ac-225-another promising cancer-fighting isotope. Already recognized internationally for over fifty years as a global leader, Canada’s research and production infrastructure, along with deep expertise in isotope technologies, place us at a critical juncture to expand our role with the global demand for isotopes doubling by 2030. The CMIE will help position Canada as a leader of the ever-growing global market for medical isotopes, which is expected to reach up to US$31 billion by 2031. “Each year, medical isotopes are used in more than 40 million procedures globally and demand is increasing worldwide,” stated TRIUMF Innovations CEO Hayashi. “With TRIUMF Innovations’ focus on commercialization, we are pleased with this new level of support for medical isotopes commercialization from Canada’s Minister of Innovation, Science and Industry, and the Canadian government.” Or, as observed by Pam Damoff, Parliamentary Secretary to the Minister of Public Safety and Member of Parliament for Oakville North—Burlington, Ontario, this latest $35 million investment and the creation of the CMIE signals yet another “major step toward building resiliency in our domestic medical production capabilities, which will help to ensure the health and safety of Canadians in the event of any potential future global supply chain disruptions.”

TRIUMF leads the way in radioisotope diagnostics and therapy

TRIUMF has been producing medical isotopes for more than 40 years, and over the past decade its Life Sciences Division has extensively expanded its radioisotope program—now producing isotopes for use in everything from Positron Emission Tomography and Single-Photon Emission Computerized Tomography (SPECT) scans to therapeutic isotopes.

Radioisotopes are an essential part of medical diagnostic procedures. In combination with imaging devices that register the gamma rays emitted from within, radioisotopes often serve as the basic ingredient of radiopharmaceutical products, which are used to detect (diagnose) or combat cardiovascular diseases and cancer cells (therapy), among many other conditions.

The TRIUMF cyclotron complex produces fluorine-18, carbon-11, actinium-225, strontium-82, germanium-68, and I-123.

TRIUMF has a smaller cyclotron, with an energy of 13 MeV (Million Electron Volts), and a larger cyclotron, with 24 MeV, which produce radioisotopes for use in PET and SPECT scans, respectively. And TRIUMF’s larger 520 MeV cyclotron has proven invaluable for targeted alpha therapy, which enables alpha-particle-emitting radioisotopes to selectively target tumor cells—even those that have spread throughout the body.

Technetium-99m is by far the most widely utilized isotope in nuclear medicine, helping to measure everything from bone density and blood flow to cardiac function and functional brain imaging. It’s used in tens of millions of diagnostic scans every year around the world, and TRIUMF licensed its Tc-99m technology (developed in response to the global shortage triggered in 2008 from the closing of the Chalk River nuclear reactor) to a successful spinoff company, ARTMS Inc.

TRIUMF continues to lead the way in the research and development of new medical isotope technologies that will enable future image-guided and personalized cancer treatments.

Radioisotopes: what they are, how they work, how they benefit patients

Medical isotopes, also known as radioisotopes, are used in more than 10,000 hospitals worldwide. Close to 90% of the procedures using these isotopes are for diagnosis. In Canada, about 1.5 million nuclear diagnostic scans are performed each year, while the U.S. accounts for about 20 million annually.

Radioisotopes are a type of chemical element that are produced through the natural decay of atoms, and every chemical element has one or more radioactive isotopes. They have the same chemical properties as stable isotopes of the same element, but they emit radiation, which can be detected. The best-known naturally occurring radioisotope is uranium. There are more than 1,000 radioactive isotopes of the various elements, about 50 of which are found in nature. The other 900-plus are produced artificially.

Radioisotopes have become an essential part of medical diagnostic procedures, especially in nuclear medicine, where radioactive tracers (radiopharmaceuticals) help assess bodily functions and diagnose and treat disease usually in combination with imaging devices, such as PET/CT (Positron Emission Tomography with Computerized Tomography). Medical technicians track these radioisotopes in the body by the gamma emissions they give off and they provide useful data on tissue or organ function to make a diagnosis.

TRIUMF has been producing medical isotopes for over 40 years now and has expanded its isotope production program to therapeutic isotopes. This new generation of radio isotopes used to precisely image and treat disease, is opening a completely new era in personalized medicine: the right medicine for the right patient at an accelerated timescale.

Medical Isotopes at TRIUMF

From TRIUMF’s earliest years as a pioneering new cyclotron facility to its modern role as Canada’s particle accelerator centre, its unique capabilities have supported medical isotope development. TRIUMF Innovations’ leadership in the Canadian Medical Isotope Ecosystem initiative is the newest piece of this exciting history- read on for a look at how it all happened!

Click (here) to go to the TRIUMF Timeline

New Training Opportunity: TRIUMF Innovations Communications Intern

TRIUMF Innovations (TI) is TRIUMF's business interface and commercialization arm, connecting Canada's particle accelerator centre to the private sector via industry partnerships, licensing, and company creation. TI provides pathways for businesses to access the expertise and infrastructure at TRIUMF and across the TRIUMF network. TRIUMF has been pushing frontiers in research for over half a century, while training the next generation of leaders in science, medicine, and industry. TI is the Co-Lead for the newly established Canadian Medical Isotope Ecosystem (CMIE), a national platform to designed to advance an accelerate innovative medical isotope technologies in Canada.

Duties:

● Help establish the CMIE website.

● Play a key role in curating, planning, and publishing TI/CMIE social media content.

● Work on promotional materials for CMIE/TI.

● Help with promoting the Canadian Medical Isotope Ecosystem (CMIE).

● Help establish the CMIE website.

● Liaison with the TI, TRIUMF and CMIE’s Communications teams.

● Establish a quarterly newsletter for TI.

● Develop contributions towards press releases.

● Contribute to the development of new and revising existing document templates and digital materials.

● Opportunities to assist in event planning projects.

Skills learned during this work experience:

● The Communications Assistant will gain experience in skills areas such as: public relations and marketing, science communications and outreach, editing and writing for clarity and content, team-based problem solving, implementing communications strategies, corporate storytelling, internal communications, media relations, event planning, communications design, resourcefulness, and project management.

● Wherever possible, the assignments will be oriented towards areas the incumbent prefers and wants to develop. We want our team members to learn new skills or enhance existing skills while at TI. In particular, the Communications Intern will learn about the wide-range of business development being conducted through TI.

Qualifications:

● Minimum two years of undergraduate or related experience.

● Clear, strategic thinker and communicator with outstanding interpersonal skills.

● At least one year of coursework in writing and composition or demonstrably comparable experience.

● Ability to translate complex topics into clear and relevant communications. Experience in journalism, corporate storytelling, digital storytelling, and/or media relations is highly sought.

● A self-starter and resourceful.

● Familiar with all elements of Microsoft Office, Adobe Creative Suite, website platforms such as WordPress and Squarespace or equivalent, content management systems, etc. Expertise in visual arts and graphic design related to public relations or marketing is a plus.

● Strong project management skills and the ability to work strategically within deadlines are both valuable assets for this position.

● Canadian Citizen or PR, and currently enrolled in school.

Skills required:

Adobe Creative Suite, Graphic Design, Journalism, Microsoft Office, Project Management, Storytelling, Undergraduate Research, WordPress.

If you are interested, please email your cover letter and resume to Tammy Chung @ tchung@triumfinnovations.ca

Deadline to apply is August 11, 2023.

TRIUMF INNOVATIONS AND THE CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION TO RECEIVE UP TO $35 MILLON IN FUNDING FOR THEIR CANADIAN MEDICIAL ISOTOPE ECOSYTEM

The Canadian Medical Isotope Ecosystem will support the development, production, advancement and distribution of isotopes, and position Canada as an international medical isotope powerhouse

VANCOUVER, BC, and HAMILTON, ON, June 27, 2023 -- TRIUMF Innovations and the Centre for Probe Development and Commercialization (CPDC) today announced they will receive up to $35 million in funding for the creation of the new Canadian Medical Isotope Ecosystem (CMIE). CMIE has been created to support advancements in Canada’s medical isotope industry through funding of projects at TRIUMF, CPDC, Bruce Power, McMaster Nuclear Reactor, Canadian Nuclear Laboratories and BWXT Medical, as well as to support the commercial development of new medical isotope technologies from researchers and SMEs across Canada.

Over the term of the funding, CMIE is expected to launch three high-demand medical isotopes and related drug products into the marketplace. It will also advance two medical isotopes from early stage to pre-clinical evaluation. CMIE is also expected to attract more than $75 million in investment, create or maintain over 600 highly skilled jobs for Canadians, and create 30 internship opportunities.

The $35 million in funding will be delivered through Innovation, Science and Economic Development’s Strategic Innovation Fund, which provides major investments in innovative projects that help grow Canada's economy for the well-being of all Canadians.

QUOTES “Our government is proud to partner with CPDC and TRIUMF Innovations as part of our Biomanufacturing and Life Sciences Strategy to create the Canadian Medical Isotope Ecosystem. Our commitment to providing Canadians with the best therapies they need to care for their health is coming to fruition, as the pandemic has shown us how important it is to have strong domestic production of pharmaceuticals. With this investment, we are making our country a major player in the global biomanufacturing and life sciences industry while creating good jobs for Canadians and stimulating the local economy." – The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry

“For more than 60 years, Canada has been a global leader in the research, development and production of medical isotopes and radiopharmaceuticals. In fact, Canada’s isotope program pioneered a new era in cancer therapy and diagnostic medicine worldwide. CPDC alone has brought more than a dozen radiopharmaceuticals into clinical development and created 4 new radiopharmaceutical companies. We are grateful to Minister Champagne for his leadership in ensuring our medical isotope industry can continue to thrive globally.” – Owen Roberts, CEO, CPDC

“Each year, medical isotopes are used in more than 40 million procedures globally and demand is increasing worldwide. CMIE will encourage the domestic production of medical isotopes, an important component used in the healthcare sector for medical diagnoses and therapies, including cancer and heart diseases. With TRIUMF Innovations’ focus on commercialization, we are pleased with this new level of support for medical isotopes commercialization from Minister Champagne and the Canadian government.” – Kathryn Hayashi, President & CEO, TRIUMF Innovations

About CPDC CPDC is a “not-for-profit” corporation founded in 2008 to advance probe (chemical agents that will carry medical isotopes to targets in the body) discovery, development and clinical research, and provide a reliable supply of radiopharmaceuticals. In the past 15 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s mission is to be a global leader in the radiopharmaceutical industry dedicated to transforming patient’s lives by advancing high quality drugs for the diagnosis and treatment of diseases. CPDC’s self-funding business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians. Learn more at www.cpdc.ca.

About TRIUMF Innovations TRIUMF Innovations Inc. is TRIUMF's business interface and commercialization arm, connecting Canada's particle accelerator centre to the private sector via industry partnerships, licensing, and company creation. TRIUMF Innovations provides pathways for businesses to access the expertise and infrastructure at TRIUMF and across the TRIUMF network. TRIUMF has been pushing frontiers in research for over half a century, while training the next generation of leaders in science, medicine, and industry. Learn more about TRIUMF's work to produce actinium-225 here. Learn more at www.triumfinnovations.ca and connect on Twitter at @TRIUMFInno.

Click (here) to go to the news relase

Media Contact
Megan Helmer
604.240.5223
mhelmer@triumfinnovations.ca

TRIUMF Innovations Newsletter

TRIUMF scientists are actively solving many current medical, environmental, and societal problems. And, as the commercial arm of TRIUMF, TRUIMF Innovations (TI) links TRIUMF’s cutting-edge science and technology to tangible business opportunities.

TI has found perhaps its most beneficial success in advancing life-saving nuclear medicine technologies, including new diagnostics and radiotherapeutic treatments that are giving late-stage cancer patients new hope, and making TRIUMF a leading enabler of building the next generation pipeline of medical isotope and nuclear medicine companies.

For instance, the first therapeutic isotope produced at TRIUMF was palladium-103 for prostate brachytherapy. And, after more than 40 years producing a millions of doses of medical isotopes for patients in Canada and around the globe, in 2020, TRIUMF entered into an agreement for increasing its production and supply of Ac-225, commonly known as “the rarest drug on earth,” to researchers and patients around the world. It now has commercial agreements with both BWXT Medical, and Fusion Pharmaceuticals.

Further TI has partnered with a pan-Canadian consortium of key stakeholders in the medical isotope industry: TRIUMF, the Centre for Probe Development, McMaster University, Canadian Nuclear Labs, Bruce Power, Saginaw-Ojibway Nation, and BWXT Medical to build a national platform to accelerate the development of a robust Canadian Medical Isotope Ecosystem and the next generation of novel isotope technologies. Canada truly punches above its weight in the medical isotope sector, thanks in no small part, to TRIUMF.

TI excels in many other areas, from commercializing particle detector technologies for use in sectors ranging from mining and security to oil and gas to radiation-testing new technologies for computing, communications, and aerospace electronics.

TI has spun off five companies, which have all gone successfully to market (with more in the pipeline). These companies include: Ideon, ARTMS, D-Pace, Micromatter, and Ikomed. The spinoffs continue to be profitable and have created dozens of permanent high-paying jobs in Canada.

For example, spinoff company Ideon Technologies uses artificial intelligence and advanced muon detectors to reduce the cost and environmental impact of geological exploration. Ideon is leading a $13.5M Digital Supercluster project and has raised $5 million in seed financing and US$16 million in a Series A. The company provides local jobs and tax revenues from its location in Richmond, British Columbia.

Further, TRIUMF Innovations:

• completed two licensing deals to venture-funded startup companies as well as two funded drug development collaborations with venture-funded Canadian and U.S. radiopharmaceutical start-ups;

• launched a training program that provides entrepreneurship training and coaching to individuals seeking to increase the commercial impact of their work;

• worked as part of a global team that worked on a 6-month project to design, test, and manufacture 4,000 COVID-19 ventilators, purchased by the Government of Canada, with public and private sector partners in Italy, the U.S., and Canada; and

• provides specialized tech-transfer licensing services to partner research institutions.

But it’s important to remember: TRIUMF Innovations does not compete with Canadian industry. Quite the contrary: we are all about building collaborations that will leverage Canada’s past investments in infrastructure and talent to reap benefits for Canada’s public and private sector. And benefiting its citizens, and people around the world.

TI’s proven deal-making expertise is coupled with the critical sectoral leadership required to build a strong ecosystem and the kind of public-private collaborations and partnerships needed to keep Canada in a leadership position in the fast-growing global medical isotope landscape. We can help Canada assert our rightful place as one of the world’s most technologically sophisticated entrepreneurial outfits.

TRIUMF INNOVATIONS BY THE NUMBERS
In 2017, TRIUMF Innovations’ mandate was expanded to encompass TRIUMF’s commercialization activities (previously it only focused on start-up company creation).

Since that time:

• 5 spin-off companies developing successful technologies, attracting investment, and generating revenue were created.

• $52 million in Seed and Series A & B financing was raised for TRIUMF spin-off companies.

Now:

• 18% of TRIUMF’s funding is from its commercialization activities born from long-standing relationships now nurtured by TI.

• TRIUMF commercialization revenues related to medical isotope innovations are expected to more than double in the next 5 years.

TRIUMF launches MOU with Dual Fluid

TRIUMF has launched a memorandum of understanding (MOU) with Canadian-German nuclear technology company Dual Fluid to advance the development of a Small Modular Reactor (SMR) based on Dual Fluid technology.

The goal of the new reactor concept is to use processed nuclear waste as fuel and to exponentially increase the performance of today’s nuclear power production technologies. This research will leverage TRIUMF’s Proton and Neutron Irradiation Facilities, PIF & NIF, and metallurgical testing capabilities. Collaboration is also planned on detector development and reactor core imaging.

Click (here) to go to the full story

Training Opportunity: TRIUMF Innovations Commercialization Interns

TRIUMF Innovations is the commercialization arm for TRIUMF, building commercialization programs using novel business models, partnerships and technology licenses. We are recruiting our second cohort of Commercialization Interns to provide students and researchers at TRIUMF with opportunities to gain valuable experience and practical skills in commercialization and entrepreneurship.

This program is open to current TRIUMF personnel who have approval from their direct supervisor and Associate Lab Director to spend 10%-20% of their time on commercialization projects over a 9-12-month period.

The Commercialization Interns will receive training and practical experience from the TRIUMF Innovations Team in:

  • Technology assessments for novel discoveries and inventions at TRIUMF
  • Building business/market cases for novel technologies
  • Confidentiality agreements and intellectual property management
  • Developing strategies for industry engagements

Qualifications/Requirements:

Must be a TRIUMF employee, graduate student or post-doctoral fellow for the entire internship

Must have pre-approval from their TRIUMF Direct Supervisor and Associate Lab Director

Desired Characteristics:

  • Proficiency in Microsoft Office Suite (Excel, Word, Powerpoint)

  • Interest and experience in business development and commercialization related to TRIUMF technologies

  • Demonstrated organizational skills, attention to detail, and accuracy

  • Excellent verbal and written communications skills

  • Self-started who can manage multiple tasks simultaneously with limited supervision

  • Ability to learn fast and achieve high level of results

  • Effective interpersonal skills
  • Ability to work in a team environment within a matrix organization

If you are interested, please email your cover letter and resume to Tammy @ tchung@triumfinnovations.ca

Deadline to apply is October 29, 2021.

If you have any questions, please do not hesitate to contact Tammy @ (604)222-7523.

TRIUMF and Fusion Pharmaceuticals announce expanded R&D collaboration for Actinium Supply Production

TRIUMF and Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have rights, including preferred access and pricing, to the resulting alpha-emitting medical isotope.

“Through its TAT platform technology, Fusion has the opportunity to unlock the full potential of actinium, an alpha-emitting isotope with the ability to deliver a potent, highly localized payload to cancer cells,” said TRIUMF Innovations CEO, Kathryn Hayashi. “With this next phase, we are solidifying our partnership with a premier developer of innovative actinium radiopharmaceuticals to deepen TRIUMF’s leadership position in isotope production and impact the cancer treatment landscape.”

TRIUMF Director and CEO, Nigel Smith, Ph.D.  added, “This marks an important milestone in the existing collaboration between Fusion and TRIUMF. Our partnership is generating new ideas and innovations that validate the important role TRIUMF has at the forefront of the global medical isotope ecosystem. Together TRIUMF and Fusion are laying the groundwork for major breakthroughs that will benefit the lives of countless patients around the world.”

Click [here] to go to the full story

Training Opportunity: TRIUMF Innovations Commercialization Interns

TRIUMF Innovations is the commercialization arm for TRIUMF, building commercialization programs using novel business models, partnerships and technology licenses. We are recruiting our second cohort of Commercialization Interns to provide students and researchers at TRIUMF with opportunities to gain valuable experience and practical skills in commercialization and entrepreneurship.

This program is open to current TRIUMF personnel who have approval from their direct supervisor and Associate Lab Director to spend 10%-20% of their time on commercialization projects over a 9-12-month period.

The Commercialization Interns will receive training and practical experience from the TRIUMF Innovations Team in:

  • technology assessments for novel discoveries and inventions at TRIUMF

  • building business/market cases for novel technologies

  • confidentiality agreements and intellectual property management

  • developing strategies for industry engagements.

 Qualifications/Requirements:

  • Must be a TRIUMF employee, graduate student or post-doctoral fellow for the entire internship

  • Must have pre-approval from their TRIUMF Direct Supervisor and Associate Lab Director

 Desired Characteristics:

  • Proficiency in Microsoft Office Suite (Excel, Word, Powerpoint)

  • Interest and experience in business development and commercialization related to TRIUMF technologies

  • Demonstrated organizational skills, attention to detail, and accuracy

  • Excellent verbal and written communications skills

  • Self-started who can manage multiple tasks simultaneously with limited supervision

  • Ability to learn fast and achieve high level of results

  • Effective interpersonal skills

  • Ability to work in a team environment within a matrix organization

 If you are interested, please email your cover letter and resume to Tammy @ tchung@triumfinnovations.ca

 Deadline to apply is April 30, 2021.

 If you have any questions, please do not hesitate to contact Tammy @ (604)222-7523.

TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope

VANCOUVER, British Columbia, December 16, 2020 – TRIUMF, Canada’s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies.

An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed. The new collaboration will enable TRIUMF to significantly increase its production and delivery of actinium-225.

Click [here]to go to the full story

Earth ‘x-ray’ pioneer Ideon Technologies closes $1.3M in seed funding Heavily oversubscribed round to fuel development of much-anticipated borehole detector

Vancouver, BC, CANADA (July 7, 2020) – Canadian start-up Ideon Technologies Inc. has raised $1.3 million CAD in seed funding through a diverse group of global investors with expertise in mining, technology, and venture fundraising, as well as the University of British Columbia (UBC)’s Seed Fund. Ideon is a world pioneer in cosmic-ray muon tomography, providing x-ray-like imaging to those who explore beneath the Earth’s surface. Ideon will deploy the new capital, combined with existing funding, to develop its new bore-hole detector, slated for commercial release in 2021.

Click [here] to go to the full story

Canadian cosmic-ray muon pioneer CRM Geotomography launches as Ideon Technologies Inc.

Agnew joins as CEO to lead strategic growth in addressing $12B+ global mineral exploration market

Vancouver, BC, CANADA (May 21, 2020) – Canadian technology start-up CRM Geotomography is getting ready to go to market and will do so under a new name – Ideon Technologies Inc. – and under the leadership of new CEO Gary Agnew.

Click [here] to go to the full story.

ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration

VANCOUVER, British Columbia and MELBOURNE, Australia, May 06, 2020 (GLOBE NEWSWIRE) -- ARTMS Products Inc. (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) announced today they have entered into a development collaboration agreement to employ ARTMS’ high activity production of Gallium-68 (68Ga) for the manufacture of Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).

Click [here] to go to the full story.

ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent

Collaboration to explore novel radiochemistry manufacture of ImaginAb’s Phase II clinical asset Los Angeles, USA and Vancouver, Canada, April 7, 2020 – ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, and ARTMS Products Inc., the global leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotopes, today announced they have entered a multi-year non-exclusive partnership to explore a novel radiochemistry manufacture of ImaginAb’s lead asset 89Zr CD8 ImmunoPET.

Under the terms of the agreement, ARTMS’ high-power technology will be deployed to enhance the manufacture of ImaginAb’s proprietary antibody 89Zr-Df-IAB22M2C (89Zr CD8 ImmunoPET).

Click [here] to go to the full story.